ArticleEuropean journal of nuclear medicine and molecular imaging2011
Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET/CT utilizing multimodality fusion techniques.
Article in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.Cancer science · 2015Trial
- PET/MRI of hypoxia and vascular function in ER-positive breast cancer: correlations with immunohistochemistry.European radiology · 2023Article
- PET Oncological Radiopharmaceuticals: Current Status and Perspectives.Molecules (Basel, Switzerland) · 2022Review
- First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer.Cancers · 2021Article
- Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts.Cancers · 2021Article
- Hypoxia and the phenomenon of immune exclusion.Journal of translational medicine · 2021Review
- Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET.Frontiers in oncology · 2021Review
- [Molecular imaging and biology · 2020Article
- Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer usingOncotarget · 2018Article
- Molecular mechanisms of hypoxia in cancer.Clinical and translational imaging · 2017Review
- Radiopharmaceuticals as probes to characterize tumour tissue.European journal of nuclear medicine and molecular imaging · 2015Review
- Imaging tumour hypoxia with positron emission tomography.British journal of cancer · 2015Review
- Measurement of hypoxia-related parameters in three sublines of a rat prostate carcinoma using dynamic (18)F-FMISO-Pet-Ct and quantitative histology.American journal of nuclear medicine and molecular imaging · 2015Article
- The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.Antioxidants & redox signaling · 2014Review
- Normoxic regulation of HIF-1α in prostate cancer.Nature reviews. Urology · 2014Article
- An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.The British journal of radiology · 2014Review
- PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.American journal of nuclear medicine and molecular imaging · 2014Review
- Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients.European journal of nuclear medicine and molecular imaging · 2013Article
- Challenges in accurate registration of 3-D medical imaging and histopathology in primary prostate cancer.European journal of nuclear medicine and molecular imaging · 2013Review
- Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer.EJNMMI research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
Abstract
purposeAs hypoxia is believed to play an important role in the development and progression of prostate cancer, we evaluated whether 18F-labeled fluoroazomycin arabinoside (18F-FAZA) would be useful to identify tumor hypoxia in resectable prostate cancer.
methodsPositron emission tomography (PET)/CT was performed on 14 patients with untreated localized primary prostate cancer 3 h post-injection of approximately 390 MBq of 18F-FAZA using forced diuresis to decrease radioactivity in the urinary bladder. Anatomical trans-pelvic coil and pre- and post-contrast 1.5 T MRI with endorectal coil were performed on the same day. Patients underwent radical prostatectomy and ex vivo 3 T MRI of the prostatectomy specimen within 14 days following in vivo imaging. Imaging results were verified by whole mount histopathology plus tissue microarray (TMA) immunohistochemical (IHC) analysis for carbonic anhydrase IX (CAIX) and hypoxia-inducible factor 1α (HIF-1α). Registration of in vivo imaging with histology was achieved using mutual information software and performing ex vivo MRI of the prostatectomy specimen and whole mount sectioning with block face photography as intermediate steps.
resultsWhole mount histology identified 43 tumor nodules, 19 of them larger than 1 ml as determined on coregistered volumes featuring 18F-FAZA, MRI, and histological 3-D image information. None of these lesions was found to be positive for CAIX or visualized by 18F-FAZA PET/CT while IHC for HIF-1α showed variable staining of tumor tissues. Accordingly, no correlation was found between 18F-FAZA uptake and Gleason scores.
conclusionOur data based on 18F-FAZA PET/CT and CAIX IHC do not support the presence of clinically relevant hypoxia in localized primary prostate cancer including high-grade disease. Activation of HIF-1α may be independent of tissue hypoxia in primary prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.